[Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
Arai
Hiroyuki
H
hiroyuki.2.arai@gsk.com
Minami
Junko
J
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002374:Catalase / Q000378:metabolism; D049109:Cell Proliferation; D002552:Cerebral Ventricles / Q000166:cytology; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use*; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D008636:Mesencephalon / Q000378:metabolism; D009414:Nerve Growth Factors / Q000378:metabolism; D018696:Neuroprotective Agents; D010300:Parkinson Disease / Q000188:drug therapy*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology; D013482:Superoxide Dismutase / Q000378:metabolism
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007211:Indoles; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D017448:Receptors, Dopamine D2; C046649:ropinirole; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione